238 terminated. 238 Phase 1, 86 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 238 | Terminated 238 |
| Phase 2 | 86 | Terminated 86 |
Follow Neoplasm Metastasis: new trials by email Literature Review of Neoplasm Metastasis trials Research Report on Neoplasm Metastasis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metastatic Melanoma [225Ac]Ac-A9-3408, [68Ga]Ga-A9T-3202 - Melanoma Metastatic, Uveal Melanoma, Metastatic | Phase 1 | Terminated | Alpha-9 Oncology USA Inc. | 5 | 2025-11-19 | 2026-08-31 |
| A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers PF-08046032, Sasanlimab - Peripheral T Cell Lymphoma, Diffuse Large B-cell Lymphoma | Phase 1 | Terminated | Pfizer | 6 | 2025-05-08 | 2026-05-08 |
| A First-in-Human Open-label, Phase I/Ib Dose Escalation and Expansion Cohort Study of EOS006215 as Monotherapy and in Combination With Pembrolizumab or Other Anticancer Treatments in Participants With Advanced Solid Tumors EOS006215, Anticancer agent - Selected Advanced Solid Tumors | Phase 1 | Terminated | iTeos Belgium SA | 3 | 2025-04-07 | 2025-08-12 |
| A Study on Tuvusertib (Oral ATR Inhibitor) in Combination With PLX038 (Topo1 Inhibitor) in Patients With Advanced Solid Tumors PLX038 + Tuvusertib - Solid Tumor | Phase 1 | Terminated | Institut Curie | 10 | 2025-01-20 | 2026-01-02 |
| A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation PRT7732 - Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1 | Terminated | Prelude Therapeutics Incorporated | 42 | 2024-11-04 | 2026-02-02 |
| A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors XL495, ADC cytotoxic agents - Solid Cancers, Solid Tumor Cancer | Phase 1 | Terminated | Exelixis | 9 | 2024-10-17 | 2025-06-25 |
| A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors BGB-B3227, Tislelizumab, Chemotherapy - Advanced Cancer, Advanced Solid Tumor | Phase 1 | Terminated | BeiGene | 35 | 2024-09-11 | 2026-03-16 |
| A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines. PF-07826390, sasanlimab, SOC (anti-PD-1 + platinum -based chemo) - Neoplasms, Non-small-cell Lung Cancer | Phase 1 | Terminated | Pfizer | 10 | 2024-09-06 | 2026-02-23 |
| A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination PF-07329640, sasanlimab, bevacizumab - Advanced or Metastatic Solid Tumors, Non-Small Cell Lung Cancer | Phase 1 | Terminated | Pfizer | 4 | 2024-05-09 | 2024-11-06 |
| A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors NKT3447 - Solid Tumor, Solid Tumor, Adult | Phase 1 | Terminated | NiKang Therapeutics, Inc. | 23 | 2024-02-23 | 2025-09-25 |
| BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid Tumors BGB-A3055, Tislelizumab, Chemotherapy - Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1 | Terminated | BeiGene | 99 | 2023-08-21 | 2026-03-13 |
| Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19) Adagrasib, nab-Sirolimus - Solid Tumor, Adult, NSCLC | Phase 1 | Terminated | Mirati Therapeutics Inc. | 6 | 2023-08-07 | 2025-04-25 |
| Safety and Tolerability of Intravenous Administration of ICVB-1042 Treatment with ICVB-1042 administered intravenously - Patients With Advanced Solid Tumors | Phase 1 | Terminated | IconOVir Bio | 17 | 2023-06-01 | 2025-04-08 |
| HB-302/HB-301 Therapy in Participants With Metastatic Castration-Resistant Prostate Cancer HB-302/HB-301 Alternating 2-Vector Therapy - Prostate Cancer Metastatic | Phase 1 / Phase 2 | Terminated | Hookipa Biotech GmbH | 12 | 2023-05-23 | 2024-06-12 |
| A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0237 in Adult Participants with Advanced Solid Tumors SIM0237 - Locally Advanced Unresectable or Metastatic Solid Tumor | Phase 1 | Terminated | Jiangsu Simcere Pharmaceutical Co., Ltd. | 192 | 2023-03-08 | 2024-12-20 |
| NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours Fosifloxuridine Nafalbenamide, Leucovorin, Pembrolizumab - Advanced Cancer, Advanced Solid Tumor | Phase 1 / Phase 2 | Terminated | NuCana plc | 19 | 2023-03-08 | 2026-07-23 |
| A Study of ASP2074 in Adults With Solid Tumors ASP2074 - Advanced Solid Tumors | Phase 1 | Terminated | Astellas Pharma Global Development, Inc. | 23 | 2023-02-28 | 2025-10-20 |
| Non-invasive Measurement of PD-L1 Levels With Positron Emission Tomography (PET) in Head and Neck Malignancies and Intracranial Metastases adnectin 18F-BMS-986192 Head and Neck Cancer, adnectin 18F-BMS-986192 Brain Metastases - Cancer Head Neck, Metastatic Cancer | Phase 1 | Terminated | Yale University | 7 | 2023-02-21 | 2024-02-15 |
| A Dose Escalation/Expansion Study of MDK-703 in Patients With Advanced or Metastatic Solid Tumors MDK-703, Checkpoint Inhibitor, Immune - Advanced or Metastatic Solid Tumors | Phase 1 / Phase 2 | Terminated | Medikine, Inc. | 26 | 2023-02-08 | 2024-05-08 |
| Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer BMF-219 - Non Small Cell Lung Cancer, Pancreatic Cancer | Phase 1 | Terminated | Biomea Fusion Inc. | 13 | 2023-01-12 | 2025-02-07 |
Showing 20 of 238. Sign in to see all of them.
Neoplasms (49) · Carcinoma, Non-Small-Cell Lung (44) · Melanoma (42) · Breast Neoplasms (32) · Colorectal Neoplasms (30) · Recurrence (28) · Lung Neoplasms (27) · Ovarian Neoplasms (22) · Carcinoma, Renal Cell (18) · Squamous Cell Carcinoma of Head and Neck (18) · Stomach Neoplasms (15) · Triple Negative Breast Neoplasms (15) · Pancreatic Neoplasms (14) · Sarcoma (14)
Neoplastic Processes (238) · Pathologic Processes (238) · Pathological Conditions, Signs and Symptoms (238) · Neoplasms (189) · Neoplasms by Site (163) · Neoplasms by Histologic Type (99) · Skin Diseases (78) · Skin and Connective Tissue Diseases (78) · Digestive System Diseases (59) · Digestive System Neoplasms (59) · Lung Diseases (59) · Respiratory Tract Diseases (59) · Respiratory Tract Neoplasms (59) · Thoracic Neoplasms (59) · Neoplasms, Glandular and Epithelial (57)
pembrolizumab (22) · Cyclophosphamide (16) · Nivolumab (12) · Gemcitabine (11) · Paclitaxel (9) · aldesleukin (9) · fludarabine (9) · Capecitabine (8) · Ipilimumab (8) · Albumin-Bound Paclitaxel (7) · Interleukin-2 (7) · Irinotecan (7) · 130-nm albumin-bound paclitaxel (6) · Cetuximab (6) · Cisplatin (6)
National Cancer Institute (NCI) (18) · M.D. Anderson Cancer Center (11) · Pfizer (11) · Novartis Pharmaceuticals (9) · Eli Lilly and Company (4) · H. Lee Moffitt Cancer Center and Research Institute (4) · Incyte Corporation (4) · Daiichi Sankyo (3) · Deciphera Pharmaceuticals, LLC (3) · Mirati Therapeutics Inc. (3) · NextCure, Inc. (3) · Sanofi (3) · Turning Point Therapeutics, Inc. (3) · AbbVie (2) · Altor BioScience (2)
United States (200) · Australia (25) · Spain (25) · France (22) · Belgium (14) · United Kingdom (14) · Canada (11) · South Korea (10) · Germany (9) · Italy (9) · Japan (8) · Taiwan (8) · Netherlands (7) · Poland (6) · China (5)
Steven A Rosenberg, M.D. (8) · Amit Mahipal, M.D. (2) · Aung Naing, MD (2) · David S Schrump, M.D. (2) · Hagop Youssoufian, MD (2) · Han Myint, MD (2) · Max W. Sung, MD (2)
PMID 23071222, PMID 23377668, PMID 23861247, PMID 24456794, PMID 24668327, PMID 25052451, PMID 25062770, PMID 25260842, PMID 25459109, PMID 25627002, PMID 25923550, PMID 26172205, PMID 28070718, PMID 29216356, PMID 29474450, PMID 30634942, PMID 30680712, PMID 30941307, PMID 31955309, PMID 32524319, PMID 32598257, PMID 32843490, PMID 33016924, PMID 33305087, PMID 33677480, PMID 33715996, PMID 33909232, PMID 34562230, PMID 34799399, PMID 34844977, PMID 34965890, PMID 35387488, PMID 35444059, PMID 36039910, PMID 36123697, PMID 36342102, PMID 36452492, PMID 36892745, PMID 37042037, PMID 37129197, PMID 37227176, PMID 37279836, PMID 37311055, PMID 37314501, PMID 37385724, PMID 37860278, PMID 37907221, PMID 37962072, PMID 38172595, PMID 39038917
2023 (5), 2016 (3), 2017 (3), 2018 (3), 2019 (2), 2015 (1), P01CA225517 (1), P30CA006516 (1), P30CA014520 (1), P30CA016059 (1), P30CA043703 (1), P30CA068485 (1), P30CA069533 (1), P30CA072720 (1), R21CA259964 (1)